Antimicrobial Resistance is a Risk for Healthy Aging

It is estimated that, in the coming decades, ten million people will die each year as victims of microorganisms that antibiotics can no longer fight

What if the medicines we rely on to overcome infections are no longer able to protect us from known diseases that would become potentially fatal? Unfortunately, that’s what we’re about to see happen. About 700,000 people die each year as victims of antimicrobial resistance – which is when medicines stop working to fight microorganisms such as fungi, viruses or bacteria that have undergone genetic changes. In the coming decades, the estimate made by the United Nations (UN) is that this number will reach ten million. It’s good to repeat it.

Sepsis, a life-threatening organ dysfunction that is caused by an unregulated response to infections, kills 11 million a year, including 3 million children. The condition is more common in hospitalized patients, or who have been recently discharged, because the hospital environment, where the use of antibiotics is widespread, is almost a “nary” for superbacteria.

Article by Michael Hodin, CEO of the Global Coalition on Aging (organization focused on issues related to longevity), in partnership with Susan Wile Schwarz and Olivia Canie, states that although this is a global health problem, it has a disproportionate weight for older people:

“Forty percent of deaths in the United States caused by antibiotic-resistant pathogens occur in the group over 65 years of age. Diseases such as pneumonia and urinary tract infection, which often affect the elderly, are also those with strains of bacteria resistant to medication”.

In 1900, pneumonia, tuberculosis and gastrointestinal infections were among the leading causes of death in the USA. Between 1950 and 1970, there was a golden age for antibiotics. However, between 2000 and 2020, the Food and Drug Administration (the North American equivalent of Anvisa) saw a drop of almost 75% in medicines of this type submitted for its approval.

Scientific innovation in the area of antibiotics is on the decline and we need a new arsenal against infections. When a bacterium survives the treatment, this resistance passes to the next generation, until the existing drugs become innocuous. Multidrug-resistant tuberculosis is a problem in one hundred countries and about 500,000 people develop the disease annually.

The global scenario is a challenge of enormous proportions:

  1. At least 30% of antibiotics prescribed in the US are unnecessary.
  2. In Italy, the inappropriate use of antibiotics ranges from 33% for individuals under 45 years of age, to 51% for the elderly between 66 and 75 years of age.
  3. In China, 84% of pharmacies sell antibiotics without a prescription.
  4. Its use is expected to increase by 200% by 2030.
  5. Globally, the economic cost of antimicrobial resistance beats 100 trillion dollars per year.

(Translated from the original Portuguese)

Source: G1 Globo

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

GCOA Sign-on Letter to Governor Spanberger: Consequences of Importing Federal Price Caps on Virginians’ Access to Medicine & Healthy Aging Opportunities

Dear Governor Spanberger: We, the undersigned organizations, bring deep, on‑the‑ground experience serving older Americans, patients managing complex and chronic conditions, and their caregivers across Virginia and nationwide. We also have a clear understanding of which policies and programs are effective and where they fall short.

New Report Summarizes State of Expert Opinions on Japan’s Adult Vaccine Policy as Population Shifts Older

The Global Coalition on Aging (GCOA), Health and Global Policy Institute (HGPI), and the Asia-Pacific Consortium for Healthy Aging and Adult Immunization (AP-CHAAI) today announced the launch of Strengthening Vaccine Policy for Healthy Aging and Economic Growth in Japan, a landscape analysis examining the state of vaccine policy in super-aging Japan. Based on a comprehensive review of over 100 policy documents, recommendations, reports, academic papers, and gray literature articles, the report, which was funded by GSK, summarizes the latest academic research and policy discourse around adult vaccines.

WSJ Letter to the Editor: How Flu Vaccine Policies Affect the Economy

Your editorial “Vinay Prasad’s Vaccine Kill Shot” (Review & Outlook, Feb. 12) points out that a recent decision by Mr. Prasad, the leader of the Food and Drug Administration’s vaccine division, will have negative consequences. Mr. Prasad’s decision to reject Moderna’s flu vaccine without even reviewing it is even worse than you describe. Denying us a new, innovative flu vaccine is horrible health policy. Innovation is at risk because, as Moderna’s CEO has said, if the largest market is off limits, investments won’t be made. But the decision will also have economic consequences. Investment in preventive health is critical as our population ages. In its April 2025 World Economic Outlook report, the International Monetary Fund dedicated an entire chapter to the need for healthier longevity as the global population ages.

Joe Biden’s ‘Cancer Moonshot’ May be Derailed by New Policies, Including His Own

For almost a decade, President Biden has championed a bold “cancer moonshot” — an initiative he first launched in 2016, revived early in his administration, and reiterated during this year’s State of the Union. It is a laudable goal, especially for an aging nation where cancer and chronic disease are on the rise. There’s just one problem: Recent federal and state policies are poised to derail the incredible progress made in oncology since 2016. A rash of policies now threatens to limit access and slow progress towards new breakthroughs.

Global Coalition on Aging, Leading G7 Government Officials, Call for Incentivized Antibiotic Innovation

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

Kishida and Biden Face a Similar Demographic Crisis

Your front page story “Japan wrestles with age-old problem as population declines at record rate” (Report, April 13) and the letter in the same edition from Tim Hill, “A gently declining population is no reason to panic”, both describe what all societies face as they modernise in the 21st century.

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.